ET Most Innovative AI Product Awards 2026: Honouring AI Innovations reshaping Life Sciences & Pharma Research

The future of healthcare innovation is increasingly being shaped by technologies that can shorten research timelines, improve scientific accuracy, and help organisations make faster, evidence-backed decisions. Across the pharmaceutical and life sciences ecosystem, companies are adopting advanced digital solutions to streamline research processes, optimise clinical trials, and accelerate the journey from discovery to treatment.

Recognising this shift, the Life Sciences & Pharma category at the ET Most Innovative AI Product Awards 2026 will honour organisations developing impactful AI-led products and platforms that are transforming scientific research and pharmaceutical innovation in India. The category focuses on solutions that are enabling measurable progress in areas such as drug discovery, clinical development, molecule screening, and personalized medicine.

To submit your nominations for Life Sciences & Pharma.


As research environments become more data-intensive and operationally complex, organisations are increasingly looking for technologies that can improve efficiency without compromising scientific rigour. AI is playing a growing role in helping companies reduce development costs, identify potential treatment pathways faster, and enhance the precision of research outcomes. The category aims to spotlight innovators that are successfully applying these technologies to solve real-world industry challenges.

The award category is open to pharmaceutical and biotech R&D teams, clinical research organisations, life sciences AI startups, computational biology companies, and AI-powered research platforms working at the intersection of healthcare and technology. It seeks to recognise organisations that are building scalable and future-ready solutions capable of delivering meaningful impact across the research and development pipeline.

Entries will be evaluated on several key parameters, including the ability of the product to reduce time or cost within drug development workflows, improve accuracy in target identification or molecule screening, and strengthen trial design and research efficiency. The judging process will also consider scientific credibility, reproducibility, and the presence of evidence-backed outcomes demonstrating the effectiveness of the solution.

To be eligible, organisations must showcase AI applications within areas such as R&D, drug discovery, or clinical trials, supported by published data, pilot studies, peer-reviewed outcomes, or validated evidence. The category is open to pharma companies, CROs, life sciences startups, and AI-driven healthcare platforms that can demonstrate practical implementation and measurable results.

With 11 categories spanning industries and business functions, the ET Most Innovative AI Product Awards 2026 aims to celebrate organisations redefining the future of innovation through AI. The Life Sciences & Pharma category highlights how emerging technologies are helping the healthcare ecosystem move towards faster discoveries, smarter research processes, and more efficient scientific advancement.

Also Read More:

AI Innovators Across Industries: Momentum builds ahead of ET Most Innovative AI Product Awards 2026

Most Innovative AI Product Awards 2026: Spotlighting AI-led transformation in Supply Chain & Manufacturing

AI in E-commerce: Enabling the next phase of growth and innovation